Cardiac allograft vasculopathy prevention: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiac | {{Cardiac allograft vasculopathy}} | ||
{{CMG}}; {{AE}} {{AN}} {{RT}} | {{CMG}}; {{AE}} {{AN}} {{RT}} | ||
Revision as of 19:23, 1 October 2014
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV includes:
- Calcineurin inhibitors, such as
- Rapamycin derivatives, such as
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil